Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Work Productivity and Activity Impairment Questionnaire - Rheumatoid Arthritis (WPAI-RA): mean presenteeism, absenteeism, and work productivity loss at baseline and least-squares mean change from baseline at week 24 and at week 52 among patients employed at baseline and at Week 24 or Week 52

From: Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

WPAI-RA questions administered to patients who were employeda
  Baseline, Mean (SD) Week 24, LSM (95% CI) Week 52, LSM (95% CI)
  MTX (N = 210) Baricitinib 4 mg (N = 159) Baricitinib 4 mg + MTX (N = 215) MTX (n = 85) Baricitinib 4 mg (n = 63) Baricitinib 4 mg + MTX (n = 105) MTX (n = 67) Baricitinib 4 mg (n = 58) Baricitinib 4 mg + MTX (n = 96)
Percent employed at time pointb, n (%) 94 (45) 67 (42) 117 (55) 80 (94) 59 (94) 94 (90) 57 (85) 55 (95) 80 (83)
Percent impairment while working due to RA (presenteeism) 49 (28) 49 (26) 50 (26) − 20 (− 25, − 15) − 29 (− 35, − 24)* − 31 (− 35, − 26)** − 26 (− 31, − 20) − 29 (− 35, − 23) − 31 (− 35, − 27)
Percent overall work impairment due to RA (work productivity loss) 53 (29) 51 (27) 55 (27) − 18 (− 24, − 13) − 29 (− 36, − 23)* − 30 (− 35, − 25)** − 23 (− 30, − 17) − 30 (− 37 − 23) − 32 (− 38, − 27)*
Percent work time missed due to RA (absenteeism) 19 (31) 14 (29) 15 (25) − 2 (− 7, 2) − 10 (− 15, − 5)* − 9 (− 12, − 5)* − 3 (− 7, 1) − 8 (− 12, − 3) − 8 (− 11, − 4)
  1. CI confidence interval, LSM least-squares mean, MTX methotrexate, RA rheumatoid arthritis
  2. aData are presented as mean (standard deviation) or LSM (95% CI)
  3. bFor weeks 24 and 52, the percentage of patients employed at baseline and who continued to be employed at that time point
  4. *p ≤ 0.05; **p ≤ 0.01 vs. MTX